A Single Dose Study Of PF-04620110 In Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the relative bioavailability of three different oral dose formulations of PF-04620110.
Epistemonikos ID: 35343a072d6dd82a4bb7d7f3bdbb4d60e182c493
First added on: May 05, 2024